1[1]Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells [J]. Nature,1988,332(6163) :411-415.
2[2]Holm P.Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstricyion[ J]. Scand Cardiovasc J Suppl,1997,46:1-40.
4[4]Ninomiya H,Yu XY,Hasegawa S,et al.Endothelin-1 induces stimulation of prostagelandin synthesis in cells obtained from canine airways by bronchoal veolar lavage [J]. Prostaglandins, 1992,43 ( 5 ): 401-411.
5[5]Yoshizumi M, Kurihara H, Sugiyawa T, et al. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells[J]. Biochem Biophys Res Commun, 1989,161(2): 859-864.
6[6]Giaid A, Yanagisawa M, Langleben D, et al. Expression of ET- 1 in the lungs of patients with pulmonary hypertension[J]. N Engl J Med, 1993,328(24): 1732-1739.
8[8]De Nucci G,Thomas R,D'Orleans JP.Pressor effects of circulating endothelin and limited by its removel in the pulmonary circulation and by the release of prostacycli and endothelium derived relaxing factor[J].Proc Nalt Acad Sci USA, 1988,85(24):9797.
9[9]Wagner DE, Nowothy P, Vierhapper H, et al. Plasma concentrations of endothelin in man:arterio-venous differences and release during venous stasis[ J]. Eur J Clin Invest, 1990,20(5) :502-505.
10[10]Kawagushi H, Sawa H, Yasuda H. Endothelin in stimulates angiotensin Ⅰ to angiotensin Ⅱ conversion in cultured pulmonary artery endothelial cells[ J]. J Mol Cell Cardiol, 1990,22(8): 839-842.
2Son YH, Jeong YT, Lee KA, et al. Roles of MAPK and NF- kaPPaB in interleukin-6 induction by lipepolysaccharide in va seular smooth muscule cells.J Cardiovasc Pharmacol, 2008,51 (1) : 71-77.
3He X, Hu JL, Li J, et al. A feedback loop in PPARr-adeno- sine A2A receptor signaling inhibits inflammation and attenuates lung damages in a mousemodel of LPSdnduced a- cute lung iniury. Cell Signal, 2013, 25 (9): 1913-1923.
4Campian ME, Hardziyenka M, Michel MC, et at. How valid are animal models to evaluate treatments for Pulmonary hy pertension. Naunyn Sehmiedebergs Arch Pharmaeol, 2006, 373(6): 391-400.
5Gruenstein DH, Bass JL. Experimental evaluation of a new articulated Amplatzer ducta| occluder device without {ahric. Catheter Cardiovasc Interv, 2009, 74(3): 482-487.
6Yanagisawa M, Kurihara H, Kimura S, et aI. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988, 332(6163): 411-415.
7Kobs RW, Chesler NC. The mechanobiology of pulmonary vascular remodeling in the congenital absence of eNOS. Bio- mech Model Mechanobiol, 2006, 5(4)~ 217-226.
8Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J,1995,9(12) ~1196-1204.
9Sato K, Rodman DM, Mcmurtry IF. Hypoxia inhibits in- creased ETB receptor-mediated NO synthesis in hypertensive rat lungs. Am J Physiol, 1999, 276(4 pt 1); L571-L581.
10Okada K, Bernstein ML, Zhang W, et al. Angiotensin-con verting enzyme inhibition delays pulmonary vascular neointimal formation. Am J Respir Crit Care Med, 1998, 158 (3) ; 939-950.
